Category Archives: Global News Feed

- Preclinical data support twice-yearly dosing in wet AMD - - Preclinical data support twice-yearly dosing in wet AMD -

Continue reading here:
Valitor Announces Presentation on Novel Anti-VEGF Antibody Conjugate and Multivalent Polymer Technology Platform at Upcoming Ophthalmology Innovation...

Carlsbad, CA, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that on December 1, 2022, it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the Nasdaq Listing Rules for continued listing on The Nasdaq Capital Market.

More:
Palisade Bio Regains Compliance with Nasdaq Listing Requirements

LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented today at the World Vaccine & Immunotherapy Congress in San Diego. Dr. Anwer highlighted the PLACCINE modality and proof-of-concept rodent and non-human primate data in SARS-CoV-2. PLACCINE is IMUNON’s non-viral, non-device plasmid DNA-based vaccine modality targeting multiple antigens from a single vector.

See original here:
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, December 6, at 8:00 a.m. ET to present initial clinical data from the Phase 1/2 RUBY trial of EDIT-301, under development for the treatment of severe sickle cell disease. The clinical data will include safety data from the first two patients and efficacy data from the first patient treated with EDIT-301.

Excerpt from:
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Continued here:
ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET

See the original post:
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host an Investor Event on December 10 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Read the original post:
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

Affirms plans to report topline Phase 1 results in 2022 and to initiate Phase 2a influenza human challenge trial in 2023

The rest is here:
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress...

The Phase 2 trial in psoriasis will explore a broad range of doses based on Phase 1 data demonstrating class-leading safety and TYK2 target coverage

Read the original post:
Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque...

Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemia Highlighting TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor to treat chronic myeloid leukemia

See original here:
Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit